Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glabellar Frown Lines: full-pipeline trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Glabellar Frown Lines: 3 US clinical trials tracked, none currently recruiting.
Glabellar Frown Lines is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Galderma R&D, running 1 of these trials.
Enrollment posture brief
Registry condition glabellar-frown-lines
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Glabellar Frown Lines has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glabellar Frown Lines on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glabellar Frown Lines is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines
Henry Ford Health System
NCT05766683
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Galderma R&D
NCT03960957
Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device
Pacira Pharmaceuticals
NCT01808742
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glabellar Frown Lines records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glabellar Frown Lines trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glabellar Frown Lines page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Glabellar Frown Lines trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Galderma R&D sponsors the most Glabellar Frown Lines trials on record, review their full trial history before evaluating a specific study. See Galderma R&D's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glabellar Frown Lines condition card totals 3 registered trials; most-linked intervention AbobotulinumtoxinA; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.